Citations (123)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Keneuoe Cecilia Nthontho, Andrew Khulekani Ndlovu, Kirthana Sharma, Ishmael Kasvosve, Daniel Louis Hertz & Giacomo Maria Paganotti. (2022) Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective. Pharmacogenomics and Personalized Medicine 15, pages 613-652.
Read now
Read now
David Eapen-John, Ayeshah G. Mohiuddin & James L. Kennedy. (2022) A potential paradigm shift in opioid crisis management: The role of pharmacogenomics. The World Journal of Biological Psychiatry 23:6, pages 411-423.
Read now
Read now
Alejandro Llanos-Cuentas, Paulo Manrrique, Angel Rosas-Aguirre, Sonia Herrera & Michelle S. Hsiang. (2022) Tafenoquine for the treatment of Plasmodium vivax malaria. Expert Opinion on Pharmacotherapy 23:7, pages 759-768.
Read now
Read now
Giovana Nakanishi, Laísa S. Bertagnolli, Murilo Pita-Oliveira, Mariana M. Scudeler, Sabrina Torres-Loureiro, Thaís Almeida-Dantas, Maria Laura C. Alves, Heithor S. Cirino & Fernanda Rodrigues-Soares. (2022) GSTM1 and GSTT1 polymorphisms in healthy volunteers – a worldwide systematic review. Drug Metabolism Reviews 54:1, pages 37-45.
Read now
Read now
Marianne Rodrigues Fernandes, Juliana Carla Gomes Rodrigues, Olalla Maroñas, Ana Latorre-Pellicer, Raquel Cruz, João Farias Guerreiro, Rommel Mario Rodriguez Burbano, Paulo Pimentel de Assumpção, Andrea Ribeiro-dos-Santos, Sidney Emanuel Batista dos Santos, Angel Carracedo & Ney Pereira Carneiro dos Santos. (2021) Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon. Pharmacogenomics and Personalized Medicine 14, pages 117-133.
Read now
Read now
Eleni Aklillu & Ephrem Engidawork. (2021) The impact of catha edulis (vahl) forssk. ex endl. (celestraceae) (khat) on pharmacokinetics of clinically used drugs. Expert Opinion on Drug Metabolism & Toxicology 17:9, pages 1125-1138.
Read now
Read now
Dmitrij Alekseevitch Sychev, Grigorij Nikolaevich Shuev, Salavat Shejhovich Suleymanov, Kristina Anatol’evna Ryzhikova, Karin Badavievich Mirzaev, Elena Anatol’evna Grishina, Natalia Evgenievna Snalina, Zhannet Alimovna Sozaeva, Anton Mikhailovich Grabuzdov & Irina Andreevna Matsneva. (2017) Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations. Pharmacogenomics and Personalized Medicine 10, pages 93-99.
Read now
Read now
Francesco Panza, Madia Lozupone, Eleonora Stella, Lucia Lofano, Carolina Gravina, Maria Urbano, Antonio Daniele, Antonello Bellomo, Giancarlo Logroscino, Antonio Greco & Davide Seripa. (2016) Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. Expert Review of Neurotherapeutics 16:12, pages 1357-1369.
Read now
Read now
Yun-Yun Zhan, Bing-Qing Liang, Hao Wang, Zhen-He Wang, Qing-Hua Weng, Da-Peng Dai, Jian-Ping Cai & Guo-Xin Hu. (2016) Effect of CYP2D6 variants on venlafaxine metabolism in vitro. Xenobiotica 46:5, pages 424-429.
Read now
Read now
Carolina Céspedes-Garro, Ingrid Fricke-Galindo, María Eugenia G Naranjo, Fernanda Rodrigues-Soares, Humberto Fariñas, Fernando de Andrés, Marisol López-López, Eva M Peñas-Lledó & Adrián LLerena. (2015) Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expert Opinion on Drug Metabolism & Toxicology 11:12, pages 1893-1905.
Read now
Read now
Rashmi R. Shah. (2015) Inter-ethnic differences in drug response: Implications for drug development and complying with drug regulation. Clinical Research and Regulatory Affairs 32:3, pages 88-98.
Read now
Read now
Alfredo Carlo Altamura, Alice Caldiroli & Massimiliano Buoli. (2015) Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders. Expert Opinion on Drug Metabolism & Toxicology 11:4, pages 649-660.
Read now
Read now
Articles from other publishers (111)
Fatemeh Saghafi, Ebrahim Salehifar, Pouneh Ebrahimi, Mohammad Reza Shiran, Ehsan Zaboli, Seyed Mojtaba Sohrevardi, Tannaz Jamialahmadi, Adeleh Sahebnasagh & Amirhossein Sahebkar. (2024) Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer. Journal of Pharmaceutical and Biomedical Analysis 238, pages 115839.
Crossref
Crossref
Abdullah Alsultan, Abdullah A Alalwan, Bashayer Alshehri, Majed Al Jeraisy, Jahad Alghamdi, Saeed Alqahtani & Ahmed A Albassam. (2023) Interethnic differences in drug response: projected impact of genetic variations in the Saudi population. Pharmacogenomics.
Crossref
Crossref
Njundu Jatta, Johnson Stanslas, Audrey Chee Hui Yong, Wen Chung Ho, Wan Syazween Lyana Wan Ahmad Kammal, Eng Wee Chua & Kang Nien How. (2023) Whole blood hydroxychloroquine: Does genetic polymorphism of cytochrome P450 enzymes have a role?. Clinical and Experimental Medicine.
Crossref
Crossref
Pura Ballester, Cristina Espadas, Susana Almenara, Jordi Barrachina, Javier Muriel, Enrique Ramos, Natalia Toral, César Belda & Ana M. Peiró. (2023) CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder: A Naturalistic Study with Extreme Phenotype Analysis. Pharmaceuticals 16:7, pages 954.
Crossref
Crossref
Luciana Bertholim-Nasciben, Marilia O. Scliar, Guilherme Debortoli, Bhooma Thiruvahindrapuram, Stephen W. Scherer, Yeda A. O. Duarte, Mayana Zatz, Guilherme Suarez-Kurtz, Esteban J. Parra & Michel S. Naslavsky. (2023) Characterization of pharmacogenomic variants in a Brazilian admixed cohort of elderly individuals based on whole-genome sequencing data. Frontiers in Pharmacology 14.
Crossref
Crossref
Di Fu, Hong-Li Guo, Ya-Hui Hu, Wei-Rong Fang, Qian-Qi Liu, Jing Xu, Dan-Dan Wu & Feng Chen. (2023) Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence. European Journal of Clinical Pharmacology.
Crossref
Crossref
Caíque ManóchioSabrina Torres-LoureiroMariana M. ScudelerBruno MiwaFernanda C. Souza-SantosFernanda Rodrigues-Soares. (2023) Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine. OMICS: A Journal of Integrative Biology 27:1, pages 6-14.
Crossref
Crossref
Médéric Mouterde, Youssef Daali, Victoria Rollason, Martina Čížková, Anwar Mulugeta, Khalid A Al Balushi, Giannoulis Fakis, Theodoros C Constantinidis, Khalid Al-Thihli, Marie Černá, Eyasu Makonnen, Sotiria Boukouvala, Said Al-Yahyaee, Getnet Yimer, Viktor Černý, Jules Desmeules & Estella S Poloni. (2022) Joint Analysis of Phenotypic and Genomic Diversity Sheds Light on the Evolution of Xenobiotic Metabolism in Humans. Genome Biology and Evolution 14:12.
Crossref
Crossref
Anmar AL-Taie, Ayşe Şeyma Büyük & Semra Sardas. (2022) Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. Pulmonary Pharmacology & Therapeutics 77, pages 102172.
Crossref
Crossref
Zhize Ye, Bingbing Chen, Nanyong Gao, Qihui Kong, Xiaoqin Hu, Zhongqiu Lu, Jianchang Qian, Guoxin Hu, Jianping Cai & Bin Wu. (2022) CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine. Frontiers in Pharmacology 13.
Crossref
Crossref
Hongyue Wang, Xinchi Ma, Bin Zhang, Yaotian Zhang, Ning Han, Linlin Wei, Chaonan Sun, Shichen Sun, Xue Zeng, Hong Guo, Yubing Li, Yanyu Zhang, Jiaming Zhao, Zilan Qin, Zhuang Liu & Na Zhang. (2021)
Chinese breast cancer patients with
CYP2D6
*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen
. Asia-Pacific Journal of Clinical Oncology 18:2.
Crossref
Crossref
Catriona Hippman, Caitlin Slomp, Emily Morris, Rolan Batallones, Angela Inglis, Prescilla Carrion, Ursula Brain, Michelle Higginson, Galen E. B. Wright, Lynda G. Balneaves, Deirdre Ryan, Corey Nislow, Colin J. D. Ross, Andrea Gaedigk, Tim F. Oberlander & Jehannine Austin. (2021) A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy. Archives of Women's Mental Health 25:2, pages 355-365.
Crossref
Crossref
Sabrina Torres-Loureiro, Mariana M Scudeler, Poliana XC Andrade, Julia Sampaio-Coelho, Igor H Nobre, Carolina Céspedes-Garro, Eduardo Tarazona-Santos, Adrián Llerena & Fernanda Rodrigues-Soares. (2022) Pharmacogenetics research in Brazil: a systematic review. Pharmacogenomics 23:4, pages 263-275.
Crossref
Crossref
Wielandt N. Ana María, Moreno C. Mauricio & Ortiz L. Lina. (2022) Uso de la farmacogenética como herramienta de precisión en psiquiatría: hacia una medicina personalizada. Revista Médica Clínica Las Condes 33:2, pages 163-173.
Crossref
Crossref
Anita Stojanović Marković, Matea Zajc Petranović, Željka Tomas, Borna Puljko, Maja Šetinc, Tatjana Škarić-Jurić & Marijana Peričić Salihović. (2022) Untangling SNP Variations within CYP2D6 Gene in Croatian Roma. Journal of Personalized Medicine 12:3, pages 374.
Crossref
Crossref
Natnicha Wankaew, Pajaree Chariyavilaskul, Monpat Chamnanphon, Adjima Assawapitaksakul, Wanna Chetruengchai, Monnat Pongpanich & Vorasuk Shotelersuk. (2022) Genotypic and phenotypic landscapes of 51 pharmacogenes derived from whole-genome sequencing in a Thai population. PLOS ONE 17:2, pages e0263621.
Crossref
Crossref
Mousa Alali, Wouroud Ismail Al-khalil, Sara Rijjal, Lana Al-Salhi, Maher Saifo & Lama A. Youssef. (2022) Frequencies of CYP2D6 genetic polymorphisms in Arab populations. Human Genomics 16:1.
Crossref
Crossref
Mauricio Moreno, Ana María Wielandt, Gonzalo Encina & Lina Ortiz. (2022) Farmacogenética en psiquiatría: estudio de variantes alélicas del CYP450 en pacientes chilenos con patología psiquiátrica. Revista Médica Clínica Las Condes 33:1, pages 58-67.
Crossref
Crossref
Alexandra G. A. Stewart, Peter A. Zimmerman & James S. McCarthy. (2021) Genetic Variation of G6PD and CYP2D6: Clinical Implications on the Use of Primaquine for Elimination of Plasmodium vivax. Frontiers in Pharmacology 12.
Crossref
Crossref
He Yu & Raj K. Singh Badhan. (2021) The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study. Journal of Pharmaceutical Sciences 110:10, pages 3507-3519.
Crossref
Crossref
Malavika Deodhar, Jacques Turgeon & Veronique Michaud. (2021) Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism. Pharmaceutics 13:9, pages 1466.
Crossref
Crossref
Tingyu Wang, Yitian Zhou & Guosheng Cao. (2021) Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes. European Journal of Clinical Pharmacology 77:8, pages 1095-1111.
Crossref
Crossref
Paula Ferreira Salles, Daiana Souza Perce-da-Silva, Atila Duque Rossi, Luisa Riehl Raposo, Aina Danaisa Ramirez Ramirez, Otílio Machado Pereira Bastos, Lilian Rose Pratt-Riccio, Gustavo Capatti Cassiano, Andrea Regina Souza Baptista, Cynthia Chester Cardoso, Dalma Maria Banic & Ricardo Luiz Dantas Machado. (2021) CYP2D6 Allele Frequency in Five Malaria Vivax Endemic Areas From Brazilian Amazon Region. Frontiers in Pharmacology 12.
Crossref
Crossref
Edward Valencia Ayala, Mylenka Chevarría Arriaga, Eduardo Barbosa Coelho, José Sandoval Sandoval & Alberto Salazar Granara. (2021)
Metabolizer phenotype prediction in different Peruvian ethnic groups through
CYP2C9
polymorphisms
. Drug Metabolism and Drug Interactions 36:2, pages 113-121.
Crossref
Crossref
Thuraya M Mutawi, Mohamed M Zedan, Raida S Yahya, Mahmoud M Zakria, Mamdouh R El-Sawi & Andrea Gaedigk. (2021)
Genetic variability of
CYP2D6, CYP3A4
and
CYP3A5
among the Egyptian population
. Pharmacogenomics 22:6, pages 323-334.
Crossref
Crossref
Fernando de Andrés, Catalina Altamirano-Tinoco, Ronald Ramírez-Roa, Carlos F Montes-Mondragón, Pedro Dorado, Eva M. Peñas-Lledó & Adrián LLerena. (2020) Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population. The Pharmacogenomics Journal 21:2, pages 140-151.
Crossref
Crossref
Ingrid Fricke-Galindo & Ramcés Falfán-Valencia. (2021) Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. Viruses 13:3, pages 413.
Crossref
Crossref
Martina Hahn, Daniel J. Müller & Sibylle C. Roll. (2020) Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. Pharmacopsychiatry 54:02, pages 81-89.
Crossref
Crossref
Anne B. Koopmans, Mario H. Braakman, David J. Vinkers, Hans W. Hoek & Peter N. van Harten. (2021) Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Translational Psychiatry 11:1.
Crossref
Crossref
D. Fernando Estrada, Amit Kumar, Christopher S. Campomizzi & Natalie Jay. 2021. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
171
192
.
F. Rodieux, M. Besson, V. Piguet, J. Desmeules & C. Samer. (2021) Prescription de tramadol chez les enfants : une bonne alternative à la codéine ?. Douleur et Analgésie 33:4, pages 247-256.
Crossref
Crossref
Heejin Kam & Hotcherl Jeong. (2020) Pharmacogenomic Biomarkers and Their Applications in Psychiatry. Genes 11:12, pages 1445.
Crossref
Crossref
Alba P Sarmiento, Pedro Dorado, Angélica Borbón, Fernando de Andrés & Adrián LLerena. (2020)
High prevalence of
CYP2D6
ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations
. Pharmacogenomics 21:17, pages 1227-1236.
Crossref
Crossref
Roberto Viviani, Irene Messina, Julia E. Bosch, Lisa Dommes, Anna Paul, Katharina L. Schneider, Catharina Scholl & Julia C. Stingl. (2020) Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity. Translational Psychiatry 10:1.
Crossref
Crossref
Maria Stella Calafato, Isabelle Austin-Zimmerman, Johan H. Thygesen, Mani Sairam, Antonio Metastasio, Louise Marston, Francisco Abad-Santos, Anjali Bhat, Jasmine Harju-Seppänen, Haritz Irizar, Eirini Zartaloudi & Elvira Bramon. (2020) The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis. The Pharmacogenomics Journal 20:5, pages 629-637.
Crossref
Crossref
Katja S. Just, Harald Dormann, Marlen Schurig, Miriam Böhme, Jochen Fracowiak, Michael Steffens, Catharina Scholl, Thomas Seufferlein, Ingo Gräff, Matthias Schwab & Julia C. Stingl. (2020) Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk?—Results from the ADRED Study. Journal of Clinical Medicine 9:6, pages 1801.
Crossref
Crossref
Carmen W. H. Chan, Bernard M. H. Law, Winnie K. W. So, Ka Ming Chow & Mary M. Y. Waye. (2020) Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. Journal of Cancer Research and Clinical Oncology 146:6, pages 1395-1404.
Crossref
Crossref
D. V. Ivashchenko, O. V. Tereshchenko, I. I. Temirbulatov, K. A. Akmalova, E. A. Grishina, M. S. Zastrozhin, L. M. Savchenko, E. A. Bryun & D. A. Sychev. (2020) Pharmacogenetics of the safety of phenazepam in alcohol withdrawal syndrome: haplotype and combinatorial analyses of polymorphic variants in the pharmacokinetic factor genes. Neurology, Neuropsychiatry, Psychosomatics 12:2, pages 17-22.
Crossref
Crossref
Ivan Skadrić & Oliver Stojković. (2019) Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population. International Journal of Legal Medicine 134:2, pages 433-439.
Crossref
Crossref
Luciana P. C. Leitão, Tatiane P. Souza, Juliana C. G. Rodrigues, Marianne R. Fernandes, Sidney Santos & Ney P. C. Santos. (2020) The Metabolization Profile of the CYP2D6 Gene in Amerindian Populations: A Review. Genes 11:3, pages 262.
Crossref
Crossref
Evelyn Marie Gutiérrez Rico, Aoi Kikuchi, Takahiro Saito, Masaki Kumondai, Eiji Hishinuma, Akira Kaneko, Chim Wai Chan, Jesse Gitaka, Tomoki Nakayoshi, Akifumi Oda, Sakae Saito, Noriyasu Hirasawa & Masahiro Hiratsuka. (2020) CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Ni-Vanuatu and Kenyan population by assessing dextromethorphan O-demethylation activity. Drug Metabolism and Pharmacokinetics 35:1, pages 89-101.
Crossref
Crossref
Sharon Rees. 2020. Neale's Disorders of the Foot and Ankle. Neale's Disorders of the Foot and Ankle
406
424
.
Fernanda Rodrigues‐Soares, Eva M. Peñas‐Lledó, Eduardo Tarazona‐Santos, Martha Sosa‐Macías, Enrique Terán, Marisol López‐López, Idania Rodeiro, Graciela E. Moya, Luis R. Calzadilla, Ronald Ramírez‐Roa, Manuela Grazina, Francisco E. Estévez‐Carrizo, Ramiro Barrantes & Adrián LLerena. (2019)
Genomic Ancestry,
CYP
2D6
,
CYP
2C9
, and
CYP
2C19
Among Latin Americans
. Clinical Pharmacology & Therapeutics 107:1, pages 257-268.
Crossref
Crossref
Palden Wangyel Dorji, Sonam Wangchuk, Kanyarat Boonprasert, Mayuri Tarasuk & Kesara Na-Bangchang. (2019) Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population. Drug Metabolism and Personalized Therapy 34:4.
Crossref
Crossref
Kelli Gerth, Sunitha Kodidela, Madeline Mahon, Sanjana Haque, Neha Verma & Santosh Kumar. (2019) Circulating Extracellular Vesicles Containing Xenobiotic Metabolizing CYP Enzymes and Their Potential Roles in Extrahepatic Cells Via Cell–Cell Interactions. International Journal of Molecular Sciences 20:24, pages 6178.
Crossref
Crossref
John A. Zebala, Shawn L. Searle, Lynn R. Webster, Matt S. Johnson, Aaron D. Schuler, Dean Y. Maeda & Stuart J. Kahn. (2019) Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. The Journal of Pain 20:10, pages 1218-1235.
Crossref
Crossref
Aarthi Manoharan, Deepak Gopal Shewade, Pradeep Anand Ravindranath, Ravi Philip Rajkumar, Vedam L Ramprasad, Surendiran Adithan & Solai Elango Damodaran. (2019)
Resequencing
CYP2D6
gene in Indian population:
CYP2D6*41
identified as the major reduced function allele
. Pharmacogenomics 20:10, pages 719-729.
Crossref
Crossref
Yeimy Viviana Ariza Márquez, Ignacio Briceño, Fabio Aristizábal, Luis Fernando Niño & Juvenal Yosa Reyes. (2019) Dynamic Effects of CYP2D6 Genetic Variants in a Set of Poor Metaboliser Patients with Infiltrating Ductal Cancer Under Treatment with Tamoxifen. Scientific Reports 9:1.
Crossref
Crossref
Balmiki Ray, Eren Ozcagli, Wolfgang Sadee & Danxin Wang. (2019) CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele). Pharmacogenetics and Genomics 29:2, pages 39-47.
Crossref
Crossref
Seung-been Lee, Marsha M. Wheeler, Karynne Patterson, Sean McGee, Rachel Dalton, Erica L. Woodahl, Andrea Gaedigk, Kenneth E. Thummel & Deborah A. Nickerson. (2018) Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genetics in Medicine 21:2, pages 361-372.
Crossref
Crossref
Simona D’Attis, Serafina Massari, Francesca Mazzei, Dominga Maio, Ilaria Vergallo, Salvatore Mauro, Mauro Minelli & Maria Pia Bozzetti. (2019) Assessment of CYP2C9, CYP2C19, and CYP2D6 Polymorphisms in Allergic Patients with Chemical Sensitivity. International Archives of Allergy and Immunology 179:3, pages 173-186.
Crossref
Crossref
Sam Mostafa, Carl M. J. Kirkpatrick, Keith Byron & Leslie Sheffield. (2018) An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. Journal of Neural Transmission 126:1, pages 5-18.
Crossref
Crossref
Blanca Bolea-Alamanac. 2019. Diversity in Global Mental Health. Diversity in Global Mental Health
41
51
.
Fernanda Rodrigues-Soares, Fernanda S. G. Kehdy, Julia Sampaio-Coelho, Poliana X. C. Andrade, Carolina Céspedes-Garro, Camila Zolini, Marla M. Aquino, Mauricio L. Barreto, Bernardo L. Horta, Maria Fernanda Lima-Costa, Alexandre C. Pereira, Adrián LLerena & Eduardo Tarazona-Santos. (2018) Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative. The Pharmacogenomics Journal 18:6, pages 749-759.
Crossref
Crossref
Minal U. Paradkar, Swarup A.V. Shah, Alpa J. Dherai, Dhanashri Shetty & Tester F. Ashavaid. (2018) Distribution of CYP2D6 genotypes in the Indian population – preliminary report. Drug Metabolism and Personalized Therapy 33:3, pages 141-151.
Crossref
Crossref
Fatemeh Saghafi, Ebrahim Salehifar, Ghasem Janbabai, Ehsan Zaboli, Akbar Hedayatizadeh‑Omran, Omolbanin Amjadi & Siavash Moradi. (2018) CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen. Biomedical Reports.
Crossref
Crossref
María-Eugenia G. NaranjoFernanda Rodrigues-SoaresEva M. Peñas-LledóEduardo Tarazona-SantosHumberto FariñasIdania RodeiroEnrique TeránManuela GrazinaGraciela E. MoyaMarisol López-LópezAlba P. SarmientoLuis R. CalzadillaRonald Ramírez-RoaRocío Ortiz-LópezFrancisco E. Estévez-CarrizoMartha Sosa-MacíasRamiro BarrantesAdrián LLerenaGraciela E. Moya, Verónica Fcrreiro, Eduardo Tarazona-Santos, Fernanda Rodrigues-Soares, Marilia O. Scliar, Mateus H Gouveia, Alba P. Sarmiento, Angélica Borbón, Ramiro Barrantes, Gerardo Jiménez-Arce, Carolina Céspedes-Garro, Idania Rodeiro, Mayra Álvárez, René Delgado, Diadelis Remirez, Bárbaro Pérez, Luis R. Calzadilla, Enrique Terán, Francisco Hernández, Santiago Terán, Rocío Ortiz-López, Augusto Rojas-Martinez, Lourdes Garza-Ocañas, Yadira X. Pérez-Páramo, Marisol López-López, Alberto Ortega-Vázquez, Nancy Monroy-Jaramillo, Helgi Jung-Cook, Ingrid Fricke-Galindo, Martha Sosa-Macías, Carlos Galaviz-Hernández, Ismael Lares-Aseff, Blanca P. Lazalde-Ramos, Ronald Ramírez-Roa, Catalina Altamirano Tinoco, Eduardo Tarazona-Santos, Roxana Zamudio, Robert H. Gilman, Manuela Grazina, Adrián LLerena, Jesús Cobaleda, Fernando de Andrés, Pedro Dorado, Humberto Fariñas, Eugenia G. Naranjo, Eva M. Peñas-Lledó & Francisco E. Estévez-Carrizo. (2018)
Interethnic Variability in
CYP2D6
,
CYP2C9
, and
CYP2C19
Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics
. OMICS: A Journal of Integrative Biology 22:9, pages 575-588.
Crossref
Crossref
Ji-Young Byeon, Young-Hoon Kim, Choong-Min Lee, Se-Hyung Kim, Won-Ki Chae, Eui-Hyun Jung, Chang-Ik Choi, Choon-Gon Jang, Seok-Yong Lee, Jung-Woo Bae & Yun Jeong Lee. (2018) CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Archives of Pharmacal Research 41:9, pages 921-930.
Crossref
Crossref
Charleen G. Don & Martin Smieško. (2018) Out‐compute drug side effects: Focus on cytochrome P450 2D6 modeling. WIREs Computational Molecular Science 8:5.
Crossref
Crossref
Monpat Chamnanphon, Andrea Gaedigk, Natchaya Vanwong, Nopphadol Nuntamool, Yaowaluck Hongkaew, Apichaya Puangpetch & Chonlaphat Sukasem. (2018)
CYP2D6
genotype analysis of a Thai population: platform comparison
. Pharmacogenomics 19:12, pages 947-960.
Crossref
Crossref
D. V. Ivashchenko, K. A. Ryzhikova, Zh. A. Sozaeva, Y. A. Pimenova, E. A. Grishina, M. S. Zastrozhin, A. D. Aguzarov, L. M. Savchenko, E. A. Bryun & D. A. Sychev. (2018) IMPACT OF CYP3A5, CYP2C9, CYP2C19, AND CYP2D6 POLYMORPHISMS ON PHENAZEPAM SAFETY IN PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME. Annals of the Russian academy of medical sciences 73:3, pages 206-214.
Crossref
Crossref
M E Moretti, D F Lato, H Berger, G Koren, S Ito & W J Ungar. (2017) A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events. The Pharmacogenomics Journal 18:3, pages 391-397.
Crossref
Crossref
J. Faria, J. Barbosa, R. Moreira, O. Queirós, F. Carvalho & R.J. Dinis-Oliveira. (2018) Comparative pharmacology and toxicology of tramadol and tapentadol. European Journal of Pain 22:5, pages 827-844.
Crossref
Crossref
Kirsten M. Pondman, Ron H.N. van Schaik & Jan van der Weide. (2018) Accurate determination of the CYP2D6 (*1/*4)xN genotype by quantitative PCR. Drug Metabolism and Personalized Therapy 33:1, pages 33-39.
Crossref
Crossref
Frédérique Rodieux, Laszlo Vutskits, Klara M. Posfay-Barbe, Walid Habre, Valérie Piguet, Jules A. Desmeules & Caroline F. Samer. (2018) When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children. Frontiers in Pharmacology 9.
Crossref
Crossref
Lazara Karelia Montané Jaime, Jeffrey Paul, Anthony Lalla, George Legall & Andrea Gaedigk. (2018)
Impact of
CYP2D6
on venlafaxine metabolism in Trinidadian patients with major depressive disorder
. Pharmacogenomics 19:3, pages 197-212.
Crossref
Crossref
Rashmi R. Shah & Andrea Gaedigk. (2017) Precision medicine: does ethnicity information complement genotype-based prescribing decisions?. Therapeutic Advances in Drug Safety 9:1, pages 45-62.
Crossref
Crossref
Theodore Wigle, Laura Jansen, Wendy Teft & Richard Kim. (2017) Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. Journal of Personalized Medicine 7:4, pages 20.
Crossref
Crossref
Anders Jørgensen, Ari Thorleifsson, Espen Jimenez-Solem, Thomas Werge & Henrik Berg Rasmussen. (2017) Severe Parkinsonism and Creatine Kinase Increase After Low-Dose Aripiprazole Treatment in a Patient of African Descent. Journal of Clinical Psychopharmacology 37:5, pages 630-631.
Crossref
Crossref
Fernando de AndrésMartha Sosa-MacíasBlanca Patricia Lazalde RamosMaría-Eugenia G. NaranjoAdrián LLerena. (2017) CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations–Where to from Here for Global Precision Medicine?. OMICS: A Journal of Integrative Biology 21:9, pages 509-519.
Crossref
Crossref
G Moya, P Dorado, V Ferreiro, M E G Naranjo, E M Peñas-Lledó & A LLerena. (2016) High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina. The Pharmacogenomics Journal 17:4, pages 378-381.
Crossref
Crossref
Ioana Todor, Dana Muntean, Maria Neag, Corina Bocsan, Anca Buzoianu, Laurian Vlase, Daniel Leucuta, Ana-Maria Gheldiu, Adina Popa & Corina Briciu. (2017) The Influence of CYP2D6 Phenotype on the Pharmacokinetic Profile of Atomoxetine in Caucasian Healthy Subjects. Acta Medica Marisiensis 63:2, pages 73-79.
Crossref
Crossref
Tom MunyerCarinda Feild. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.
Mamoonah Chaudhry, Marco Alessandrini, Jacobus Rademan, Tyren M Dodgen, Francois E Steffens, Danie G van Zyl, Andrea Gaedigk & Michael S Pepper. (2017)
Impact of
CYP2D6
genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study
. Pharmacogenomics 18:5, pages 433-443.
Crossref
Crossref
Lana Ganoci, Tamara Božina, Nikica Mirošević Skvrce, Mila Lovrić, Petar Mas & Nada Božina. (2017)
Genetic polymorphisms of cytochrome P450 enzymes:
CYP2C9
,
CYP2C19
,
CYP2D6
,
CYP3A4
, and
CYP3A5
in the Croatian population
. Drug Metabolism and Personalized Therapy 32:1, pages 11-21.
Crossref
Crossref
S Ryu, S Park, JH Lee, YR Kim, HS Na, HS Lim, HY Choi, IY Hwang, JG Lee, ZW Park, WY Oh, JM Kim & SE Choi. (2017)
A Study on
CYP2C19
and
CYP2D6
Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans
. Clinical and Translational Science 10:2, pages 93-101.
Crossref
Crossref
Natchaya VanwongNattawat NgamsamutSadeep MedhasiApichaya PuangpetchMontri ChamnanphonTeerarat Tan-kamYaowaluck HongkaewPenkhae LimsilaChonlaphat Sukasem. (2017) Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology 27:2, pages 185-191.
Crossref
Crossref
Hao Wang, Da-Peng Dai, Peng Sun, Li-Ping Xu, Bing-Qing Liang, Jian-Ping Cai & Guo-Xin Hu. (2017) Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in?vitro. Chemico-Biological Interactions 264, pages 10-15.
Crossref
Crossref
Margaret J. Livingstone, Cornelius B. Groenewald, Jennifer A. Rabbitts & Tonya M. Palermo. (2017) Codeine use among children in the United States: a nationally representative study from 1996 to 2013. Pediatric Anesthesia 27:1, pages 19-27.
Crossref
Crossref
Pedro DoradoIdilio GonzálezMaría Eugenia G. NaranjoFernando de AndrésEva María Peñas-LledóLuis Ramón CalzadillaAdrián LLerena. (2017)
Lessons from Cuba for Global Precision Medicine:
CYP2D6
Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism
. OMICS: A Journal of Integrative Biology 21:1, pages 17-26.
Crossref
Crossref
Andrea Gaedigk, Katrin Sangkuhl, Michelle Whirl-Carrillo, Teri Klein & J. Steven Leeder. (2017) Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine 19:1, pages 69-76.
Crossref
Crossref
Giulio Napolitano, Julia C. Stingl, Matthias Schmid & Roberto Viviani. (2017) Predicting CYP2D6 phenotype from resting brain perfusion images by gradient boosting. Psychiatry Research: Neuroimaging 259, pages 16-24.
Crossref
Crossref
Elizabeth J. J. Berm, Judith J. Gout-Zwart, Jos Luttjeboer, Bob Wilffert & Maarten J. Postma. (2016) A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy. PLOS ONE 11:12, pages e0169065.
Crossref
Crossref
Dmitriy A. Sychev, Irina S. Burashnikova & Ruslan E. Kazakov. (2016)
1846G>A polymorphism of
CYP2D6
gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study
. Drug Metabolism and Personalized Therapy 31:4, pages 205-212.
Crossref
Crossref
Nancy MorenoCarlos Flores-AnguloCecilia VillegasYuselin Mora. (2016) CYP2D6 variability in populations from Venezuela. Drug Metabolism and Personalized Therapy 31:4, pages 181-189.
Crossref
Crossref
Fernando De AndrésSantiago TeránFrancisco HernándezEnrique TeránAdrián LLerena. (2016) To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype–Phenotype Concordance and Discordance in the Ecuadorian Population. OMICS: A Journal of Integrative Biology 20:12, pages 699-710.
Crossref
Crossref
Martha Sosa-Macías, Enrique Teran, William Waters, Martha M Fors, Catalina Altamirano, Helgi Jung-Cook, Carlos Galaviz-Hernández, Marisol López-López, Diadelis Remírez, Graciela E Moya, Francisco Hernández, Humberto Fariñas, Ronald Ramírez, Carolina Céspedes-Garro, Eduardo Tarazona-Santos & Adrián LLerena. (2016) Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America. Pharmacogenomics 17:16, pages 1741-1747.
Crossref
Crossref
Ingrid Fricke-Galindo, Alberto Ortega-Vázquez, Nancy Monroy-Jaramillo, Pedro Dorado, Helgi Jung-Cook, Eva Peñas-Lledó, Adrián LLerena & Marisol López-López. (2016) Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers. Pharmacogenomics 17:17, pages 1913-1930.
Crossref
Crossref
Nuala A. Helsby. (2016) CYP2C19 and CYP2D6 genotypes in Pacific peoples. British Journal of Clinical Pharmacology 82:5, pages 1303-1307.
Crossref
Crossref
Carolina Céspedes-Garro, María-Eugenia G Naranjo, Fernanda Rodrigues-Soares, Adrián LLerena, Jorge Duconge, Lazara K Montané-Jaime, Hilda Roblejo, Humberto Fariñas, María de los A Campos, Ronald Ramírez, Víctor Serrano, Carmen I Villagrán & Eva M Peñas-LLedó. (2016) Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. Pharmacogenomics 17:15, pages 1707-1724.
Crossref
Crossref
M E G Naranjo, F de Andrés, A Delgado, J Cobaleda, E M Peñas-Lledó & A LLerena. (2016) High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies. The Pharmacogenomics Journal 16:5, pages 485-490.
Crossref
Crossref
Ying SuBing-qing LiangYan-lin FengYunyun ZhanErmin GuXinxin ChenDa-Peng DaiGuo-xin HuJian-ping Cai. (2016)
Assessment of 25
CYP2D6
alleles found in the Chinese population on propafenone metabolism in vitro
. Canadian Journal of Physiology and Pharmacology 94:8, pages 895-899.
Crossref
Crossref
Roseann S. GammalKristine R. CrewsCyrine E. HaidarJames M. HoffmanDonald K. BakerPatricia J. BarkerJeremie H. Estepp, Deqing Pei, Ulrich Broeckel, Winfred Wang, Mitchell J. Weiss, Mary V. RellingJane Hankins. (2016) Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. Pediatrics 138:1.
Crossref
Crossref
Ibrahim A. Abdel-Hamid, Karl-Erik Andersson, Marcel D. Waldinger & Tarek H. Anis. (2016) Tramadol Abuse and Sexual Function. Sexual Medicine Reviews 4:3, pages 235-246.
Crossref
Crossref
Ingrid Fricke-Galindo, Helgi Jung-Cook, Adrián LLerena & Marisol López-López. (2016) Interethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: a report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics). Drug Metabolism and Personalized Therapy 31:2, pages 61-81.
Crossref
Crossref
I Fricke-Galindo, C Céspedes-Garro, F Rodrigues-Soares, M E G Naranjo, Á Delgado, F de Andrés, M López-López, E Peñas-Lledó & A LLerena. (2015) Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. The Pharmacogenomics Journal 16:2, pages 113-123.
Crossref
Crossref
Natchaya Vanwong, Nattawat Ngamsamut, Yaowaluck Hongkaew, Nopphadol Nuntamool, Apichaya Puangpetch, Montri Chamnanphon, Ananya Sinrachatanant, Penkhae Limsila & Chonlaphat Sukasem. (2016) Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. Drug Metabolism and Pharmacokinetics 31:2, pages 156-162.
Crossref
Crossref
Olalla Maroñas, Ana Latorre, Joaquín Dopazo, Munir Pirmohamed, Cristina Rodríguez-Antona, Gérard Siest, Ángel Carracedo & Adrián LLerena. (2016) Progress in pharmacogenetics: consortiums and new strategies. Drug Metabolism and Personalized Therapy 31:1, pages 17-23.
Crossref
Crossref
Jie Cai, Da-Peng Dai, Pei-Wu Geng, Shuang-Hu Wang, Hao Wang, Yun-Yun Zhan, Xiang-Xin Huang, Guo-Xin Hu & Jian-Ping Cai. (2016)
Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms
In Vitro
. Basic & Clinical Pharmacology & Toxicology 118:3, pages 190-199.
Crossref
Crossref
Julie A. Cox, Mick D. Fellows, Tsuneo Hashizume & Paul A. White. (2016)
The utility of metabolic activation mixtures containing human hepatic post-mitochondrial supernatant (S9) for
in vitro
genetic toxicity assessment
. Mutagenesis 31:2, pages 117-130.
Crossref
Crossref
Rashmi R Shah, Andrea Gaedigk, Adrián LLerena, Michel Eichelbaum, Julia Stingl & Robert L Smith. (2016) CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics 17:3, pages 259-275.
Crossref
Crossref
Mónica Acuña, Eric Pinto, Paulina Olivares & Carolina Ríos. (2016) Genetic Variants of Cytochrome <b><i>CYP2D6</i></b> in Two Mixed Chilean Populations. Human Heredity 82:1-2, pages 16-20.
Crossref
Crossref
Susannah L. Collins, Daniel F. Carr & Munir Pirmohamed. (2015) Advances in the Pharmacogenomics of Adverse Drug Reactions. Drug Safety 39:1, pages 15-27.
Crossref
Crossref
Eva E. Peñas-Lledó, Aurea Delgado & Adrián LLerena. 2016. Understanding Suicide. Understanding Suicide
415
433
.
Nelson Varela, Luis A. Quiñones, Jana Stojanova, Joselyn Garay, Dante Cáceres, Silvia Cespedes, Jaime Sasso & Carla Miranda. (2015) Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses. Pharmacological Research 101, pages 124-129.
Crossref
Crossref
Bonnie A. Fijal, Yingying Guo, Si G. Li, Jonna Ahl, Taro Goto, Yoko Tanaka, Laura K. Nisenbaum & Himanshu P. Upadhyaya. (2015) CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. The Journal of Clinical Pharmacology 55:10, pages 1167-1174.
Crossref
Crossref
Adrián LLerena & Eva M. Peñas-Lledó. (2015) Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice. Drug Metabolism and Personalized Therapy 30:3, pages 143-145.
Crossref
Crossref
Ann K. Daly. (2015) Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. Drug Metabolism and Personalized Therapy 30:3, pages 165-174.
Crossref
Crossref
Adrián LLerena. (2015) Population pharmacogenetics and global health. Drug Metabolism and Personalized Therapy 30:2, pages 73-74.
Crossref
Crossref
Moran Lazaryan, Chen Shasha-Zigelman, Zachi Dagan & Matitiahu Berkovitch. (2015) Codeine should not be prescribed for breastfeeding mothers or children under the age of 12. Acta Paediatrica 104:6, pages 550-556.
Crossref
Crossref
Martha Sosa-Macias, Graciela E Moya, Adrián LLerena, Ronald Ramírez, Enrique Terán, Eva M Peñas-LLedó, Eduardo Tarazona-Santos, Carlos Galaviz-Hernández, Carolina Céspedes-Garro & Hildaura Acosta. (2015) Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics 16:7, pages 673-676.
Crossref
Crossref